A Randomized, Double-Blind Placebo-Controlled Phase 2 Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy.

Trial Profile

A Randomized, Double-Blind Placebo-Controlled Phase 2 Study of CS-7017 in Colorectal Cancer Patients Who Have Achieved Disease Control Following First-Line Chemotherapy.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Aug 2017

At a glance

  • Drugs Efatutazone (Primary)
  • Indications Colorectal cancer
  • Focus Therapeutic Use
  • Sponsors Daiichi Sankyo Inc
  • Most Recent Events

    • 20 Nov 2013 Planned end date changed from 1 Mar 2013 to 1 Mar 2014 as reported by ClinicalTrials.gov.
    • 16 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 07 Mar 2012 Planned end date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top